{
    "clinical_study": {
        "@rank": "14762", 
        "arm_group": [
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp,  trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results."
            }, 
            {
                "arm_group_label": "Minoxidil 0.5% /2ml", 
                "arm_group_type": "Active Comparator", 
                "description": "After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp,  trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to investigate the effectiveness and safety of mesotherapy for the treatment\n      of female pattern alopecia.\n\n        -  Sixty female subjects between 18 and 65 years diagnosed with female pattern hair loss\n           will undergo mesotherapy sessions weekly for ten weeks.\n\n        -  One group will receive 0.5%/2ml minoxidil application  and a control group will receive\n           application of placebo (saline 0.9%).\n\n        -  Biopsy of the scalp, trichogram and trichoscopy (Fotofinder) will be performed before\n           and 08 weeks after treatment as a method objective evaluation of the response"
        }, 
        "brief_title": "Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Female Pattern Alopecia", 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a trial that aims to analyze the efficacy and safety  of mesotherapy with minoxidil\n      0,5% versus placebo for androgenetic alopecia in female patients.\n\n      The patients and the investigators who analyzes complementary exams are blind.\n\n        -  Clinical criteria, photo, 4mm biopsia, trichogram and trichoscopy  are perfomed before\n           patients are randomized into two arms :\n\n             1. Group 1 (Placebo):\n\n                30 patients who will have intradermal  injections in the scalp of saline 0.9%\n\n             2. Group 2 (Active Drug):\n\n                30 patients who will receive intradermal injections in the scalp  with minoxidil\n                0.5%/2ml\n\n                Eight weeks after the last session patients will be recruited for repeat the exams\n                and  perform a self-assessment of both the effect on hair growth and the effect on\n                hair loss."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women from 18 to 65 years old\n\n          -  Androgenetic Alopecia (female pattern hair loss)\n\n        Exclusion Criteria:\n\n          -  patients with alopecia areata or cicatricial alopecia\n\n          -  pregnancy and breastfeeding\n\n          -  have undergone any specific treatment in the last 06 months\n\n          -  use of drugs with anti-androgenic properties\n\n          -  patients with signs or symptoms of hyper-androgynism"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655108", 
            "org_study_id": "HUB-UnB TrichoGroup 1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Minoxidil 0.5% /2ml", 
                "description": "Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks", 
                "intervention_name": "Minoxidil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "description": "Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks", 
                "intervention_name": "Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Minoxidil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Androgenetic Alopecia", 
            "Mesotherapy", 
            "Minoxidil", 
            "Trichogram"
        ], 
        "lastchanged_date": "September 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brasilia", 
                    "country": "Brazil", 
                    "state": "Distrito Federal", 
                    "zip": "71917-720"
                }, 
                "name": "University of Brasilia"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA", 
        "overall_official": [
            {
                "affiliation": "University of Brasilia", 
                "last_name": "Barbara Uzel, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Brasilia", 
                "last_name": "Izelda Costa, Ph.D", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Six weeks after the last session of mesotherapy patients will be subjected to control examinations to evaluation of results. Scalp biopsy to determine the terminal-vellus ratio, trichogram to assess the percentage of anagen hair, telogen and dystrophic and Trichoscan will be performed to see if there was improvement in hair density", 
            "measure": "Increase in hair density", 
            "safety_issue": "No", 
            "time_frame": "Sixteen weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655108"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brasilia University Hospital", 
            "investigator_full_name": "Izelda Maria Carvalho Costa", 
            "investigator_title": "Adjunct Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "In each session of mesotherapy,  blood pressure and cardiac frequency at baseline and 10 min after  application of the drug will be measured to assess the safety profile of the solution of minoxidil to 0.5% when injected intradermally.\nAny adverse effect reported will be recorded on specific clinical form", 
            "measure": "Mesotherapy safety", 
            "safety_issue": "Yes", 
            "time_frame": "six months"
        }, 
        "source": "Brasilia University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brasilia University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}